GlassScriptPhysician profile
David P Rodgers
NPI 1619934346
$10,915.83
in general payments reported to CMS, 2019-2025
49 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2020: $1,890 · 2021: $1,994 · 2022: $1,572 · 2023: $1,210 · 2024: $1,283 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459 · Education: $13.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.48 |
| Education | $13.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,986.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $998.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $920.81 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $877.41 | 2019-2025 | Mounjaro, Trulicity |
| Pfizer INC. | $652.95 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $645.83 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $460.86 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $429.81 | 2021-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $421.24 | 2019-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $345.87 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $304.12 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $275.00 | 2019-2023 | |
| Amarin Pharma, INC. | $273.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.57 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $239.40 | 2020-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.